Glenmark Pharmaceuticals Limited (GLENMARK) receives Establishment Inspection Report from U.S. FDA for its Goa facility with Voluntary Action Indicated status.
Glenmark Pharmaceuticals Limited (GLENMARK) secures U.S. FDA approval to expand RYALTRIS® use for children aged 6 to less than 12 years.
Glenmark Pharmaceuticals Inc., USA launches Olanzapine for Injection, 10 mg/vial, Single-Dose Vial. Learn about the strategic focus on injectables and market.
Glenmark Pharmaceuticals Limited (GLENMARK) advances its multi-country Phase 3 clinical trial for Trastuzumab rezetecan in platinum-resistant ovarian cancer.
Glenmark Pharmaceuticals Limited launches Methylene Blue Injection USP in USA, expanding access to affordable healthcare solutions.
Glenmark Pharmaceuticals Limited (GLENMARK) launches Winlevi® cream in key European markets, marking first NCE launch and strengthening dermatology portfolio.
Glenmark Pharmaceuticals Limited announces new development candidate ISB 2301, a first-in-class multispecific immune cells activator targeting solid tumors.
Glenmark Pharmaceuticals Limited (GLENMARK) launches Vancomycin Hydrochloride for Injection in USA, expanding access to quality, affordable medicines.